The rates of ypN0 and pCR were significantly lower for patients with ER+HER2− cancers than for those with ER−PR−HER2− (TNBC) (p < 0.0001) or HER2+ cancers (p = 0.007), suggesting that these biomarker groups had a superior response to NAC. The gene discussed is ERBB2; the disease is cancer.